Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
XENE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$26.74 - $46.00
Previous CloseN/A
Volume41.45K
Average Volume (3M)955.09K
Market Cap
$2.94B
Enterprise Value$1.99B
Total Cash (Recent Filing)$487.55M
Total Debt (Recent Filing)$8.71M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 05, 2025EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding77,105,800
10 Day Avg. Volume1,024,804
30 Day Avg. Volume955,090
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue198.92
Enterprise Value/Gross Profit267.19
Enterprise Value/Ebitda-6.30
Forecast
1Y Price Target
$54.40Price Target Upside40.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company announced the completion of patient recruitment in X-TOLE2 and reaffirmed its guide for top-line data, which should be received positively by investors.
Drug DevelopmentAzetukalner’s strong and durable efficacy, novel mechanism, convenient dosing, and positive mood impact are seen as key differentiators among anti-seizure medications.
Financial PerformanceThe company ended the quarter with approximately $625 million in cash, which management believes should fund operations into 2027.
Bears Say
Investment And PatienceFurther investment and patience are required for azetukalner, despite its strong Phase 2b data and differentiated mechanism.
Market CompetitionPotential competition from BioHaven Pharmaceuticals with its Kv7 channel modulator, BHV-7000, which is expected to readout results in focal onset epilepsy.
Regulatory ChallengesXENE will refine timelines for trial results once the trial's last patient has been randomized, indicating potential regulatory challenges.
Xenon News
XENE FAQ
What was Xenon’s price range in the past 12 months?
Xenon lowest stock price was $26.74 and its highest was $46.00 in the past 12 months.
What is Xenon’s market cap?
Xenon’s market cap is $2.94B.
When is Xenon’s upcoming earnings report date?
Xenon’s upcoming earnings report date is Nov 05, 2025 which is in 72 days.
How were Xenon’s earnings last quarter?
Xenon released its earnings results on Aug 11, 2025. The company reported -$1.07 earnings per share for the quarter, missing the consensus estimate of -$0.987 by -$0.083.
Is Xenon overvalued?
According to Wall Street analysts Xenon’s price is currently Undervalued.
Does Xenon pay dividends?
Xenon does not currently pay dividends.
What is Xenon’s EPS estimate?
Xenon’s EPS estimate is -1.15.
How many shares outstanding does Xenon have?
Xenon has 77,105,800 shares outstanding.
What happened to Xenon’s price movement after its last earnings report?
Xenon reported an EPS of -$1.07 in its last earnings report, missing expectations of -$0.987. Following the earnings report the stock price went up 5.512%.
Which hedge fund is a major shareholder of Xenon?
Currently, no hedge funds are holding shares in XENE
Xenon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.40 (40.06% Upside)
$54.40 (40.06% Upside)
Blogger Sentiment
Bullish
XENE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 113.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $91.4 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.51%
12-Months-Change
Fundamentals
Return on Equity
-37.65%
Trailing 12-Months
Asset Growth
-23.72%
Trailing 12-Months
Company Description
Xenon
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
XENE Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Xenon Pharmaceuticals, with significant progress in their epilepsy and neuropsychiatric programs, strong financial health, and promising early-stage pipeline developments. However, there are some uncertainties in the bipolar depression program and regulatory filing timeline. Overall, the positive advancements strongly outweigh the noted uncertainties.View all XENE earnings summariesXENE Stock 12 Month Forecast
Average Price Target
$54.40
▲(40.06% Upside)
Technical Analysis
Merus
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―
MoonLake Immunotherapeutics
―
Ownership Overview
0.14% Insiders
29.82% Mutual Funds
57.28% Other Institutional Investors
6.69% Public Companies and
Individual Investors